mRNA–LNP COVID-19 Vaccines: Insights from Conventional Immunisation & Drug-Targeting Principles

• Applying drug-targeting and immunisation principles to reduce off-target toxicity and improve tolerability of mRNA–LNP vaccines
• Designing formulations and dosing strategies that enable safe repeat administration without diminishing immune response
• Optimising LNP composition and delivery to enhance therapeutic durability and sustain protective efficacy over time

Speakers:

Janos Szebeni

Group Head at the Department of Translational Medicine

Semmelweis University